Wednesday, October 14, 2026
Via News Knowledge File

Apple Inc.

organization80% conf.·synced Oct 14, 2026

Technology company producing consumer electronics and software

60
sourced metrics
2073
relationships
20
stated objectives
2
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Price 52 Week Low
246.63USD
Oct 13, 2026reference only
Stock Price
341.27USD
Oct 13, 2026reference only
Market Cap
4980555808600USD
Oct 13, 2026reference only
Price 52 Week High
341.27USD
Oct 13, 2026reference only
Stock Return Ytd
25.9%
Oct 13, 2026reference only
Shares Outstanding
14594180000.0shares
Jul 17, 2026reference only
Net Income
29789000000.0USD
Jun 27, 2026reference only
Stockholders Equity
107520000000.0USD
Jun 27, 2026reference only
Total Liabilities
275746000000.0USD
Jun 27, 2026reference only
Gross Profit
54770000000.0USD
Jun 27, 2026reference only
Eps
2.02USD_per_share
Jun 27, 2026reference only
Revenue
109417000000.0USD
Jun 27, 2026reference only
Cost Of Revenue
54647000000.0USD
Jun 27, 2026reference only
Cash
39544000000.0USD
Jun 27, 2026reference only
Total Assets
383266000000.0USD
Jun 27, 2026reference only
Operating Income
35695000000.0USD
Jun 27, 2026reference only
Rd Expense
11729000000.0USD
Jun 27, 2026reference only
Operating Cash Flow
53925000000.0USD
Dec 27, 2025reference only

Stated objectives

Expand facilities and teams across 8 US states over four years

source
target: 8 states with 20,000 new hires by 2029-01-01 00:00:00stated

Additional US R&D investment in AI and silicon engineering for semiconductors

source
stated

Manufacture Apple's proprietary chips exclusively in Arizona at TSMC Fab 21

source
stated

Shift to making key iPhone components internally

source
stated

Invest $600 billion over four years to bring manufacturing to U.S., supporting 450,000 supplier jobs and hiring 20,000 employees

source
target: 600 billion USD investment, 20,000 new hires by 2029-01-01 00:00:00stated

Double-digit year-over-year iPhone sales growth for December quarter (Q1 FY2026)

source
target: double_digit_growth by 2025-12-01 00:00:00stated

December quarter revenue to be best ever for company and iPhone

source
target: Record revenue by 2025-12-31 00:00:00stated

Release advanced AI features and launch AI wearable devices including glasses, pendant, and AirPods built around Siri

source
stated

Invest $600 billion in U.S. manufacturing through the American Manufacturing Program

source
target: 600 billion USD stated

Diversify production beyond China

source
stated

Relationship graph · 2073 connections

Developed by
820
Competes with
256
Covered by
158
Supplies to
146
Employs
144
Invested in
75
Customer of
73
headquartered in
47

Where sources disagree

We surface conflicts between sources rather than hiding them.

timing conflictunresolved

The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.

Via News coverage

This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com